NURS 6521 ADVANCED
PHARMACOLOGY – MIDTERM
COMPREHENSIVE EXAM BANK: 200
VERIFIED QUESTIONS WITH CORRECT
ANSWERS & RATIONALES (2026/2027
ACADEMIC YEAR)
SECTION 1: PHARMACOKINETICS &
PHARMACODYNAMICS (Questions 1-15)
1. First-pass metabolism occurs primarily in which organ?
• A) Kidneys
• B) Lungs
• C) Liver
• D) Intestines
Rationale: First-pass metabolism occurs when a drug is metabolized in the liver
before reaching systemic circulation, reducing its bioavailability. Drugs administered
orally pass through the hepatic portal system and undergo metabolism by hepatic
enzymes, particularly the CYP450 system. This is why some drugs require higher oral
doses than intravenous doses to achieve therapeutic effects .
2. Bioavailability refers to:
• A) The distribution of a drug to target tissues
• B) The amount of active drug that reaches systemic circulation
• C) The rate at which a drug is metabolized
• D) The time required for drug excretion
Rationale: Bioavailability is the fraction of the administered drug dose that reaches
systemic circulation in its unchanged, active form. Intravenous administration has
100% bioavailability because the drug bypasses absorption barriers. Oral
bioavailability is affected by first-pass metabolism, drug solubility, and formulation
factors .
,3. A drug's half-life (t½) determines:
• A) Its potency at receptor sites
• B) Its duration of action and dosing interval
• C) The rate of drug absorption
• D) The extent of protein binding
Rationale: Half-life is the time required for plasma concentration to decrease by
50%. It determines dosing frequency and time to reach steady state. Drugs with
shorter half-lives require more frequent dosing, while longer half-lives allow once-
daily or extended-interval dosing .
4. A drug with a short half-life typically requires:
• A) Less frequent dosing
• B) More frequent dosing to maintain therapeutic levels
• C) No maintenance dosing
• D) A loading dose only
Rationale: Drugs with short half-lives are eliminated rapidly, requiring frequent
dosing to maintain concentrations within the therapeutic range. Examples include
morphine (t½ 2-4 hours), requiring q4h dosing. Extended-release formulations may
be used to overcome this limitation .
5. The volume of distribution (Vd) indicates:
• A) The extent of drug elimination
• B) The extent of drug spread into body tissues
• C) The rate of drug metabolism
• D) The degree of protein binding
Rationale: Volume of distribution is the theoretical volume that would be necessary
to contain the total amount of administered drug at the same concentration
observed in the plasma. A large Vd indicates extensive distribution into tissues, while
a small Vd suggests the drug remains primarily in the vascular compartment .
,6. A patient is taking a drug that is a weak base. In which compartment will the
drug MOST likely accumulate?
• A) Plasma (pH 7.4)
• B) Gastric juice (pH 1.5)
• C) Breast milk (pH 6.8)
• D) Urine (pH 5.5)
Rationale: Weak bases are more lipid-soluble in alkaline environments but become
ionized (trapped) in acidic compartments. The gastric juice is highly acidic (pH 1.5),
so a weak base will ionize and be trapped there, leading to accumulation. This is an
example of ion trapping, which affects drug distribution and excretion .
7. A patient is a poor metabolizer of CYP2D6. Which drug is MOST likely to
cause toxicity at standard doses?
• A) Codeine
• B) Tamoxifen
• C) Metoprolol
• D) Clopidogrel
Rationale: Metoprolol is metabolized by CYP2D6; poor metabolizers have higher
plasma levels, leading to excessive beta-blockade (bradycardia, hypotension).
Codeine and tamoxifen are prodrugs requiring CYP2D6 activation, so poor
metabolizers would have reduced effects. Clopidogrel is activated by CYP2C19, not
CYP2D6 .
8. What is the primary mechanism by which drug metabolites are conjugated in
Phase II metabolism?
• A) Cytochrome P450 oxidation
• B) Reduction reactions
• C) Glucuronidation and sulfation
• D) Hydrolysis
Rationale: Phase II metabolism involves conjugation reactions where the drug or
Phase I metabolite is combined with endogenous substrates such as glucuronic acid
, (glucuronidation) or sulfate (sulfation). These reactions increase water solubility,
facilitating renal excretion. Glucuronidation is a major pathway for many drugs
including morphine and acetaminophen .
9. A 68-year-old patient with cirrhosis and hypoalbuminemia is prescribed
warfarin. The nurse practitioner understands that the free (active) drug
concentration will be:
• A) Decreased due to increased protein binding capacity
• B) Increased due to reduced albumin available for protein binding
• C) Unchanged because protein binding does not affect drug activity
• D) Decreased because the liver metabolizes the drug more rapidly
Rationale: Hypoalbuminemia (low serum albumin) reduces available protein-binding
sites for highly protein-bound drugs like warfarin (99% protein-bound). This results in
a higher concentration of free, pharmacologically active drug, increasing the risk of
toxicity even at "normal" total drug levels. The NP must monitor for bleeding signs
and consider dose reduction .
10. Which route of administration bypasses first-pass hepatic metabolism?
• A) Oral
• B) Sublingual
• C) Rectal
• D) Enteral
Rationale: Sublingual administration allows the drug to be absorbed directly into the
systemic circulation through the mucous membranes, bypassing the hepatic portal
system and first-pass metabolism. Oral and enteral routes are subject to first-pass
metabolism. Rectal administration partially bypasses first-pass metabolism but is less
reliable .
11. A drug that is 96% protein bound has what fraction available for
pharmacologic activity?
• A) 96%
PHARMACOLOGY – MIDTERM
COMPREHENSIVE EXAM BANK: 200
VERIFIED QUESTIONS WITH CORRECT
ANSWERS & RATIONALES (2026/2027
ACADEMIC YEAR)
SECTION 1: PHARMACOKINETICS &
PHARMACODYNAMICS (Questions 1-15)
1. First-pass metabolism occurs primarily in which organ?
• A) Kidneys
• B) Lungs
• C) Liver
• D) Intestines
Rationale: First-pass metabolism occurs when a drug is metabolized in the liver
before reaching systemic circulation, reducing its bioavailability. Drugs administered
orally pass through the hepatic portal system and undergo metabolism by hepatic
enzymes, particularly the CYP450 system. This is why some drugs require higher oral
doses than intravenous doses to achieve therapeutic effects .
2. Bioavailability refers to:
• A) The distribution of a drug to target tissues
• B) The amount of active drug that reaches systemic circulation
• C) The rate at which a drug is metabolized
• D) The time required for drug excretion
Rationale: Bioavailability is the fraction of the administered drug dose that reaches
systemic circulation in its unchanged, active form. Intravenous administration has
100% bioavailability because the drug bypasses absorption barriers. Oral
bioavailability is affected by first-pass metabolism, drug solubility, and formulation
factors .
,3. A drug's half-life (t½) determines:
• A) Its potency at receptor sites
• B) Its duration of action and dosing interval
• C) The rate of drug absorption
• D) The extent of protein binding
Rationale: Half-life is the time required for plasma concentration to decrease by
50%. It determines dosing frequency and time to reach steady state. Drugs with
shorter half-lives require more frequent dosing, while longer half-lives allow once-
daily or extended-interval dosing .
4. A drug with a short half-life typically requires:
• A) Less frequent dosing
• B) More frequent dosing to maintain therapeutic levels
• C) No maintenance dosing
• D) A loading dose only
Rationale: Drugs with short half-lives are eliminated rapidly, requiring frequent
dosing to maintain concentrations within the therapeutic range. Examples include
morphine (t½ 2-4 hours), requiring q4h dosing. Extended-release formulations may
be used to overcome this limitation .
5. The volume of distribution (Vd) indicates:
• A) The extent of drug elimination
• B) The extent of drug spread into body tissues
• C) The rate of drug metabolism
• D) The degree of protein binding
Rationale: Volume of distribution is the theoretical volume that would be necessary
to contain the total amount of administered drug at the same concentration
observed in the plasma. A large Vd indicates extensive distribution into tissues, while
a small Vd suggests the drug remains primarily in the vascular compartment .
,6. A patient is taking a drug that is a weak base. In which compartment will the
drug MOST likely accumulate?
• A) Plasma (pH 7.4)
• B) Gastric juice (pH 1.5)
• C) Breast milk (pH 6.8)
• D) Urine (pH 5.5)
Rationale: Weak bases are more lipid-soluble in alkaline environments but become
ionized (trapped) in acidic compartments. The gastric juice is highly acidic (pH 1.5),
so a weak base will ionize and be trapped there, leading to accumulation. This is an
example of ion trapping, which affects drug distribution and excretion .
7. A patient is a poor metabolizer of CYP2D6. Which drug is MOST likely to
cause toxicity at standard doses?
• A) Codeine
• B) Tamoxifen
• C) Metoprolol
• D) Clopidogrel
Rationale: Metoprolol is metabolized by CYP2D6; poor metabolizers have higher
plasma levels, leading to excessive beta-blockade (bradycardia, hypotension).
Codeine and tamoxifen are prodrugs requiring CYP2D6 activation, so poor
metabolizers would have reduced effects. Clopidogrel is activated by CYP2C19, not
CYP2D6 .
8. What is the primary mechanism by which drug metabolites are conjugated in
Phase II metabolism?
• A) Cytochrome P450 oxidation
• B) Reduction reactions
• C) Glucuronidation and sulfation
• D) Hydrolysis
Rationale: Phase II metabolism involves conjugation reactions where the drug or
Phase I metabolite is combined with endogenous substrates such as glucuronic acid
, (glucuronidation) or sulfate (sulfation). These reactions increase water solubility,
facilitating renal excretion. Glucuronidation is a major pathway for many drugs
including morphine and acetaminophen .
9. A 68-year-old patient with cirrhosis and hypoalbuminemia is prescribed
warfarin. The nurse practitioner understands that the free (active) drug
concentration will be:
• A) Decreased due to increased protein binding capacity
• B) Increased due to reduced albumin available for protein binding
• C) Unchanged because protein binding does not affect drug activity
• D) Decreased because the liver metabolizes the drug more rapidly
Rationale: Hypoalbuminemia (low serum albumin) reduces available protein-binding
sites for highly protein-bound drugs like warfarin (99% protein-bound). This results in
a higher concentration of free, pharmacologically active drug, increasing the risk of
toxicity even at "normal" total drug levels. The NP must monitor for bleeding signs
and consider dose reduction .
10. Which route of administration bypasses first-pass hepatic metabolism?
• A) Oral
• B) Sublingual
• C) Rectal
• D) Enteral
Rationale: Sublingual administration allows the drug to be absorbed directly into the
systemic circulation through the mucous membranes, bypassing the hepatic portal
system and first-pass metabolism. Oral and enteral routes are subject to first-pass
metabolism. Rectal administration partially bypasses first-pass metabolism but is less
reliable .
11. A drug that is 96% protein bound has what fraction available for
pharmacologic activity?
• A) 96%
